消息面上，国家医保局近日公告，2025年国家基本医保目录及商保创新药目录调整专家评审工作已结 束，包括药明巨诺的倍诺达在内的5款CAR-T药物均通过了专家评审。据悉，CAR-T治疗由于"一针超百 万元"的高昂定价始终未能进入基本医保目录。截至目前，CAR-T疗法已经基本形成了以商业医疗保险 为主体、特病特药保险为补充、金融分期及各类救助方案为辅的多元支付格局。 药明巨诺-B(02126)盘中涨近7%，截至发稿，涨6.1%，报4.35港元，成交额728.67万港元。 公开资料显示，药明巨诺的倍诺达已被70余款商业医疗险产品纳入，公司也对外回应称，公司CAR-T产 品会积极参加2025年医保和商保创新药目录申报工作。业内人士普遍认为，此次5款CAR-T产品集体通 过专家评审，释放出积极信号，显示监管层在提高前沿疗法可及性上的决心。 ...

Core Viewpoint - China Biotechnology Services (08037) announced that its indirect non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., will present the Phase I clinical trial results of LY007 cell injection at two major international conferences in 2025, highlighting its potential to fill the treatment gap in CD20 CAR-T therapy [1] Group 1: Efficacy and Safety - LY007 features a unique OX40 co-stimulation signal design that significantly enhances T cell expansion and anti-tumor activity. Phase I clinical trial data shows that 92% of 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma experienced tumor reduction or disappearance, with a best complete response rate (BCRR) of 75%. One patient who failed CD19 CAR-T treatment achieved complete remission without severe cytokine release syndrome or neurotoxicity [2] Group 2: Differentiated Indication Strategy - LY007 offers a new treatment option for patients who failed CD19 CAR-T therapy or are CD19-negative relapsed. The CAR-T cells peaked at 46% to 80% of CD3+ T cells in patients. Shanghai Longyao plans to further promote international multicenter clinical research for LY007 at the International Conference on Malignant Lymphoma and the European Hematology Association meeting, exploring collaborations with European and American institutions. The company has laid out 14 global patents to support product commercialization and expansion into solid tumor indications. Over the past year, the Phase I clinical research results of LY007 have been presented at major global oncology and hematology conferences, indicating recognition and attention in the global academic field [3]